Verified discoveries, trials, and approvals for this cancer type. Every story separates evidence strength, regulatory status, and guideline position.
In the randomized, phase 3 ECOG-ACRIN E1910 trial, adding blinatumomab to consolidation chemotherapy significantly extended overall survival compared with chemotherapy alone in adults with MRD-negative B-cell precursor ALL — the…
Primary source cited
Last reviewed
In the single-arm Study ASTX727-07, an all-oral combination of decitabine/cedazuridine (Inqovi) plus venetoclax produced a complete remission rate of 41.6% (and a combined complete-remission-or-partial-hematologic-recovery rate of 52.5%) in older or…
Primary source cited
Last reviewed
In the randomized, phase 3 BRUIN-CLL-321 trial, pirtobrutinib -- the first and only non-covalent (reversible) BTK inhibitor -- significantly extended progression-free survival compared with standard chemoimmunotherapy options in patients with…
Primary source cited
Last reviewed
In the randomized, phase 3 ECOG-ACRIN E1910 trial, adding blinatumomab to consolidation chemotherapy significantly extended overall survival compared with chemotherapy alone in adults with MRD-negative B-cell precursor ALL — the…
Primary source cited
Last reviewed
In the single-arm Study ASTX727-07, an all-oral combination of decitabine/cedazuridine (Inqovi) plus venetoclax produced a complete remission rate of 41.6% (and a combined complete-remission-or-partial-hematologic-recovery rate of 52.5%) in older or…
Primary source cited
Last reviewed
In the randomized, phase 3 BRUIN-CLL-321 trial, pirtobrutinib -- the first and only non-covalent (reversible) BTK inhibitor -- significantly extended progression-free survival compared with standard chemoimmunotherapy options in patients with…
Primary source cited
Last reviewed
Regulatory approval is separate from evidence certainty and from guideline position. Approval applies only to the exact indication stated in each jurisdiction record.
ECOG-ACRIN E1910 trial primary results: blinatumomab in MRD-negative B-cell precursor ALL (NEJM). DOI 10.1056/NEJMoa2312948, PMID 39047240.
Applies to the exact indication stated.
Fully Oral Combination of Decitabine/Cedazuridine (ASTX727) Plus Venetoclax for the Treatment of Newly Diagnosed Acute Myeloid Leukemia in Patients Ineligible for Intensive Chemotherapy (Blood, ASH Annual Meeting). DOI 10.1182/blood-2024-198541.
Applies to the exact indication stated.
Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321) (Journal of Clinical Oncology). DOI 10.1200/JCO-25-00166, PMID 40479620.
Applies to the exact indication stated.
In the single-arm Study ASTX727-07, an all-oral combination of decitabine/cedazuridine (Inqovi) plus venetoclax produced a complete remission rate of 41.6% (and a combined complete-remission-or-partial-hematologic-recovery rate of 52.5%) in older or…
Primary source cited
Last reviewed
CancerDiscoveries summarizes verified records in its database. Absence of a listing here does not establish that a treatment lacks regulatory authorization or access.